Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAPTOP: Insulin Glargine + OADs vs Premixed Insulin in T2DM
NCT00783744Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2001
- Primary completion
- Aug 2003
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Frequency of subjects with HbA1c ≤ 7.0 % and > 7.0 % at 28 weeks. Started Dec 2001; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00783744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00783744.